These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1689281)

  • 41. Quantification of angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model.
    Gaudric A; N'guyen T; Moenner M; Glacet-Bernard A; Barritault D
    Ophthalmic Res; 1992; 24(3):181-8. PubMed ID: 1407961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialized and intact rabbit eye.
    Fredj-Reygrobellet D; Elena PP; Moenner M; Baudouin C; Ettaiche M; Barritault D; Lapalus P
    Curr Eye Res; 1989 Nov; 8(11):1141-52. PubMed ID: 2612201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biosynthesis of basement membrane collagen by rabbit corneal endothelium in vitro.
    Kefalides NA; Cameron JD; Tomichek EA; Yanoff M
    J Biol Chem; 1976 Feb; 251(3):730-3. PubMed ID: 1249049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of the basic fibroblast growth factor low affinity binding site in cardiac sarcolemmal vesicles.
    Ross CR; Hale CC
    Life Sci; 1990; 46(24):1809-15. PubMed ID: 2113602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis.
    Gullino PM
    Acta Oncol; 1995; 34(3):439-41. PubMed ID: 7540024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Basic fibroblast growth factor high and low affinity binding sites in developing mouse brain, hippocampus and cerebellum.
    Fayein NA; Courtois Y; Jeanny JC
    Biol Cell; 1992; 76(1):1-13. PubMed ID: 1294285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A morphological study of the rabbit corneal assay.
    Wilting J; Christ B
    Ann Anat; 1992 Dec; 174(6):549-56. PubMed ID: 1282307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Presence of basic fibroblast growth factor in corneal epithelium.
    van Setten G; Fagerholm P; Cuevas-Sanchez P
    Ophthalmic Res; 1995; 27(6):317-21. PubMed ID: 8927303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stimulatory effects of basic fibroblast growth factor on DNA synthesis in the human embryonic cornea.
    Hyldahl L; Schofield PN; Engström W
    Development; 1990 Jul; 109(3):605-11. PubMed ID: 2401214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of corneal vascularization.
    Huang AJ; Li DQ; Li CH; Shang TY; Hernandez E
    Ocul Surf; 2005 Oct; 3(4 Suppl):S190-3. PubMed ID: 17216117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nature of Bowman's layer.
    Bettman JW
    N Engl J Med; 1970 Feb; 282(6):344. PubMed ID: 4188926
    [No Abstract]   [Full Text] [Related]  

  • 52. Vascular growth factor binding kinetics to the endothelial cell basement membrane, with a kinetics-based correction for substrate binding.
    Clyne AM; Edelman ER
    Cytotechnology; 2009 Jul; 60(1-3):33. PubMed ID: 19639390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of extracellular matrix in mouse and human corneal neovascularization.
    Barbariga M; Vallone F; Mosca E; Bignami F; Magagnotti C; Fonteyne P; Chiappori F; Milanesi L; Rama P; Andolfo A; Ferrari G
    Sci Rep; 2019 Oct; 9(1):14272. PubMed ID: 31582785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular underpinnings of corneal angiogenesis: advances over the past decade.
    Abdelfattah NS; Amgad M; Zayed AA; Hussein H; Abd El-Baky N
    Int J Ophthalmol; 2016; 9(5):768-79. PubMed ID: 27275438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).
    Stevenson W; Cheng SF; Dastjerdi MH; Ferrari G; Dana R
    Ocul Surf; 2012 Apr; 10(2):67-83. PubMed ID: 22482468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging techniques to treat corneal neovascularisation.
    Menzel-Severing J
    Eye (Lond); 2012 Jan; 26(1):2-12. PubMed ID: 21979862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel aspects of corneal angiogenic and lymphangiogenic privilege.
    Ellenberg D; Azar DT; Hallak JA; Tobaigy F; Han KY; Jain S; Zhou Z; Chang JH
    Prog Retin Eye Res; 2010 May; 29(3):208-48. PubMed ID: 20100589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mediators of ocular angiogenesis.
    Qazi Y; Maddula S; Ambati BK
    J Genet; 2009 Dec; 88(4):495-515. PubMed ID: 20090210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
    Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
    Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).
    Azar DT
    Trans Am Ophthalmol Soc; 2006; 104():264-302. PubMed ID: 17471348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.